These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38524636)

  • 1. Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.
    Almutair A; Almulhem B
    Front Endocrinol (Lausanne); 2024; 15():1294264. PubMed ID: 38524636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.
    Warncke K; Kummer S; Raile K; Grulich-Henn J; Woelfle J; Steichen E; Prinz N; Holl RW
    J Clin Endocrinol Metab; 2019 Mar; 104(3):845-855. PubMed ID: 30535056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3).
    Becker M; Galler A; Raile K
    Pediatrics; 2014 Mar; 133(3):e775-9. PubMed ID: 24567025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
    Terakawa A; Chujo D; Yasuda K; Ueno K; Nakamura T; Hamano S; Ohsugi M; Tanabe A; Ueki K; Kajio H
    Medicine (Baltimore); 2020 Aug; 99(35):e21939. PubMed ID: 32871938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment switch from multiple daily insulin injections to sulphonylureas in an African young adult diagnosed with HNF1A MODY: a case report.
    Katte JC; Dehayem MY; Colclough K; Sobngwi E
    J Med Case Rep; 2024 Oct; 18(1):506. PubMed ID: 39420387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of Diabetes Mellitus Type MODY5 as a Feature of 17q12 Deletion Syndrome.
    Yaşar Köstek H; Özgüç Çömlek F; Gürkan H; Özkayın EN; Tütüncüler Kökenli F
    J Clin Res Pediatr Endocrinol; 2024 May; 16(2):205-210. PubMed ID: 36511482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the management of patients with HNF1B MODY and multisystem manifestations: the cases of two adolescent boys.
    Vourdoumpa A; Paltoglou G; Mertzanian A; Sertedaki A; Sakou II; Karanasios S; Karavanaki K; Charmandari E
    Hormones (Athens); 2024 Sep; 23(3):439-445. PubMed ID: 38980656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of digenic maturity onset diabetes of the young with heterozygous variants in both HNF1Α and HNF1Β genes.
    Patouni K; Cinek O; Pruhova S; Elblova L; Xatzipsalti M; Sertedaki A; Vazeou A
    Eur J Med Genet; 2021 Sep; 64(9):104264. PubMed ID: 34161864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
    Tan X; Cao X; Zhou M; Zou P; Hu J
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)].
    Datz N; Nestoris C; von Schütz W; Danne T; Driesel AJ; Maringa M; Kordonouri O
    Dtsch Med Wochenschr; 2011 May; 136(21):1111-5. PubMed ID: 21590629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
    Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.
    Garg SK; Kaur G; Haider Z; Rodriquez E; Beatson C; Snell-Bergeon J
    Diabetes Technol Ther; 2024 Mar; 26(3):184-189. PubMed ID: 38444317
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.